JP2015520763A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520763A5
JP2015520763A5 JP2015513217A JP2015513217A JP2015520763A5 JP 2015520763 A5 JP2015520763 A5 JP 2015520763A5 JP 2015513217 A JP2015513217 A JP 2015513217A JP 2015513217 A JP2015513217 A JP 2015513217A JP 2015520763 A5 JP2015520763 A5 JP 2015520763A5
Authority
JP
Japan
Prior art keywords
cdb
administered
breast
breast tumor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015513217A
Other languages
English (en)
Japanese (ja)
Other versions
JP6322623B2 (ja
JP2015520763A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/060801 external-priority patent/WO2013175009A1/en
Publication of JP2015520763A publication Critical patent/JP2015520763A/ja
Publication of JP2015520763A5 publication Critical patent/JP2015520763A5/ja
Application granted granted Critical
Publication of JP6322623B2 publication Critical patent/JP6322623B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015513217A 2012-05-25 2013-05-24 乳房腫瘍の予防および処置のための酢酸ウリプリスタル Expired - Fee Related JP6322623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305586.5 2012-05-25
EP12305586 2012-05-25
PCT/EP2013/060801 WO2013175009A1 (en) 2012-05-25 2013-05-24 Ulipristal acetate for prevention and treatment of breast tumors

Publications (3)

Publication Number Publication Date
JP2015520763A JP2015520763A (ja) 2015-07-23
JP2015520763A5 true JP2015520763A5 (enExample) 2016-07-14
JP6322623B2 JP6322623B2 (ja) 2018-05-09

Family

ID=48471021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513217A Expired - Fee Related JP6322623B2 (ja) 2012-05-25 2013-05-24 乳房腫瘍の予防および処置のための酢酸ウリプリスタル

Country Status (10)

Country Link
US (2) US20150133418A1 (enExample)
EP (1) EP2854817B1 (enExample)
JP (1) JP6322623B2 (enExample)
KR (1) KR20150039130A (enExample)
AU (1) AU2013265163B2 (enExample)
CA (1) CA2874530A1 (enExample)
ES (1) ES2672727T3 (enExample)
HU (1) HUE037889T2 (enExample)
IL (1) IL235847B (enExample)
WO (1) WO2013175009A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102864826B1 (ko) 2023-02-07 2025-09-29 재단법인 아산사회복지재단 항암제에 대한 치료 반응성을 예측하기 위한 조성물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5965377A (en) 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
US6514713B1 (en) 2001-07-03 2003-02-04 Hybritech Incorporated Methods of detecting BRCA1 mutations
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
US20060111577A1 (en) 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets

Similar Documents

Publication Publication Date Title
CN103945849B (zh) 癌症的联合治疗
JP2017039771A5 (enExample)
JP2019534308A5 (enExample)
JP2020509024A5 (enExample)
RU2012153963A (ru) Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами
JP2016517434A5 (enExample)
JP2013520971A5 (enExample)
JP2015524444A5 (enExample)
JP2018184465A5 (enExample)
JP2019530713A5 (enExample)
JP2020522549A5 (enExample)
JP2017526697A5 (enExample)
CN104688720A (zh) 绿原酸在制备治疗黑色素瘤的药物中的用途及治疗黑色素瘤的药物
JP2019530648A5 (enExample)
JP2019526632A5 (enExample)
JP2021502392A5 (enExample)
CN101700247A (zh) 利用脱氢表雄酮甾体及抗毒蕈碱药物治疗呼吸道疾病及肺病的组合物、制剂和试剂盒
JP2015520763A5 (enExample)
JP2019507786A5 (enExample)
JP2017516829A5 (enExample)
WO2005084387A3 (en) Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
CN104225463B (zh) 一种用于治疗激素依赖性肿瘤的中药组合物及其制备方法
CN104940259B (zh) 康定独活或其提取物在制备促凝血类药物中的用途
CA2576926A1 (en) Use of midostaurin for treating gastrointestinal stromal tumors
CN101579389A (zh) 一种治疗骨质疏松症的药物组合物